Premium
ADJUVANT IMMUNOTHERAPY IN BRONCHOGENIC CARCINOMA *
Author(s) -
Takita H.,
Minowada J.,
Han T.,
Takada M.,
Lane W. W.
Publication year - 1976
Publication title -
annals of the new york academy of sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1976.tb41713.x
Subject(s) - health department , medicine , library science , gerontology , public health , pathology , computer science
Ten patients with locally far advanced bronchogenic carcinoma were treated with autologous tumor vaccine after a radical surgical resection. Three of 10 patients treated with tumor vaccine are alive (median survival of 26 months) whereas all nine patients in the control group are dead (median survival of 6.5 months). Active immunotherapy adjunct to radical surgery appeared to improve cellular immunity of the treated patients in the postoperative period, and the migration inhibition test indicated sensitization of treated patients against their tumor.